文献速递心脑血管急症消化、代谢与肾脏急症

老年房颤患者中口服抗凝药疗效与安全性随痴呆状态比较

Comparative Effectiveness and Safety of Oral Anticoagulants by Dementia Status in Older Patients With Atrial Fibrillation.
PubMed 文献 · JAMA Netw Open · 2023-03-01
一句话结论在老年房颤合并痴呆患者中,阿哌沙班较华法林、达比加群或利伐沙班与更低的大出血和缺血性卒中复合终点率相关。

该回顾性比较疗效研究纳入1 160 462例65岁及以上房颤患者,采用1:1倾向评分匹配,比较阿哌沙班、达比加群、利伐沙班和华法林。在痴呆患者中,与阿哌沙班相比,华法林(aHR 1.5,95%CI 1.3-1.7)、达比加群(aHR 1.5,95%CI 1.2-2.0)和利伐沙班(aHR 1.3,95%CI 1.1-1.5)的6个月缺血性卒中或大出血复合终点率更高。风险差尺度上,痴呆患者的绝对风险增加大于无痴呆患者,尤其在大出血方面。作者认为这些发现支持在合并痴呆的房颤患者中使用阿哌沙班抗凝。

要点

  • 痴呆房颤患者中,华法林较阿哌沙班复合终点率更高(95.7 vs 64.2事件/1000人年;aHR 1.5,95%CI 1.3-1.7)。
  • 痴呆房颤患者中,达比加群较阿哌沙班复合终点率更高(84.5 vs 54.9事件/1000人年;aHR 1.5,95%CI 1.2-2.0)。
  • 痴呆房颤患者中,利伐沙班较阿哌沙班复合终点率更高(87.4 vs 68.5事件/1000人年;aHR 1.3,95%CI 1.1-1.5)。
  • 风险差尺度上,痴呆患者绝对风险增加更大:华法林vs阿哌沙班校正RD 29.8(95%CI 18.4-41.1)vs 无痴呆16.0(95%CI 13.6-18.4)事件/1000人年。
  • 作者认为这些发现支持在合并痴呆的房颤患者中使用阿哌沙班抗凝治疗。

适用人群与场景

  • 65岁及以上房颤患者,数据来自Optum Clinformatics Data Mart(2013年1月1日至2021年6月30日)、IBM MarketScan Research Database(2013年1月1日至2020年12月31日)和Centers for Medicare & Medicaid Services维护的Medicare索赔数据库(住院、门诊和药房;2013年1月1日至2017年12月31日)。
  • 总人群1 160 462例,平均(SD)年龄77.4(7.2)岁,50.2%为男性,80.5%为白人,7.9%有痴呆。

研究设计与关键结果

  • 研究类型:回顾性比较疗效研究,采用1:1倾向评分匹配,随机效应Meta分析合并数据库。
  • 三个新使用者比较队列:华法林vs阿哌沙班(501 990例;平均[SD]年龄78.1[7.4]岁;50.2%女性)、达比加群vs阿哌沙班(126 718例;平均[SD]年龄76.5[7.1]岁;52.0%男性)、利伐沙班vs阿哌沙班(531 754例;平均[SD]年龄76.9[7.2]岁;50.2%男性)。
  • 主要终点为口服抗凝药启动后6个月内缺血性卒中或大出血的复合终点,合并数据库。
  • 痴呆患者中,华法林较阿哌沙班复合终点率更高(95.7 vs 64.2事件/1000人年;aHR 1.5,95%CI 1.3-1.7)。
  • 痴呆患者中,达比加群较阿哌沙班复合终点率更高(84.5 vs 54.9事件/1000人年;aHR 1.5,95%CI 1.2-2.0)。
  • 痴呆患者中,利伐沙班较阿哌沙班复合终点率更高(87.4 vs 68.5事件/1000人年;aHR 1.3,95%CI 1.1-1.5)。
  • 风险差尺度:华法林vs阿哌沙班校正RD在痴呆患者为29.8(95%CI 18.4-41.1)事件/1000人年,无痴呆患者为16.0(95%CI 13.6-18.4)事件/1000人年;达比加群vs阿哌沙班对应为29.6(95%CI 11.6-47.6)vs 5.8(95%CI 1.1-10.4)事件/1000人年;利伐沙班vs阿哌沙班对应为20.5(95%CI 9.9-31.1)vs 15.9(95%CI 11.4-20.3)事件/1000人年。
  • 上述模式在大出血方面较缺血性卒中更明显。

证据类型、等级与局限

  • 证据类型:回顾性比较疗效研究。
  • 作者结论:阿哌沙班较其他口服抗凝药与更低的大出血和缺血性卒中率相关;痴呆患者中其他口服抗凝药较阿哌沙班的绝对风险增加大于无痴呆患者,尤其在大出血方面;这些发现支持在合并痴呆的房颤患者中使用阿哌沙班抗凝治疗。

对床旁实践的改变

  • 对于合并痴呆的老年房颤患者,作者认为这些发现支持使用阿哌沙班进行抗凝治疗。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

IMPORTANCE: The development of an optimal stroke prevention strategy, including the use of oral anticoagulant (OAC) therapy, is particularly important for patients with atrial fibrillation (AF) who are living with dementia, a condition that increases the risk of adverse outcomes. However, data on the role of dementia in the safety and effectiveness of OACs are limited.

OBJECTIVE: To assess the comparative safety and effectiveness of specific OACs by dementia status among older patients with AF.

DESIGN, SETTING, AND PARTICIPANTS: This retrospective comparative effectiveness study used 1:1 propensity score matching among 1 160 462 patients 65 years or older with AF. Data were obtained from the Optum Clinformatics Data Mart (January 1, 2013, to June 30, 2021), IBM MarketScan Research Database (January 1, 2013, to December 31, 2020), and Medicare claims databases maintained by the Centers for Medicare & Medicaid Services (inpatient, outpatient, and pharmacy; January 1, 2013, to December 31, 2017). Data analysis was performed from September 1, 2021, to May 24, 2022.

EXPOSURES: Apixaban, dabigatran, rivaroxaban, or warfarin.

MAIN OUTCOMES AND MEASURES: Composite end point of ischemic stroke or major bleeding events over the 6-month period after OAC initiation, pooled across databases using random-effects meta-analyses.

RESULTS: Among 1 160 462 patients with AF, the mean (SD) age was 77.4 (7.2) years; 50.2% were male, 80.5% were White, and 7.9% had dementia. Three comparative new-user cohorts were established: warfarin vs apixaban (501 990 patients; mean [SD] age, 78.1 [7.4] years; 50.2% female), dabigatran vs apixaban (126 718 patients; mean [SD] age, 76.5 [7.1] years; 52.0% male), and rivaroxaban vs apixaban (531 754 patients; mean [SD] age, 76.9 [7.2] years; 50.2% male). Among patients with dementia, compared with apixaban users, a higher rate of the composite end point was observed in warfarin users (95.7 events per 1000 person-years [PYs] vs 64.2 events per 1000 PYs; adjusted hazard ratio [aHR], 1.5; 95% CI, 1.3-1.7), dabigatran users (84.5 events per 1000 PYs vs 54.9 events per 1000 PYs; aHR, 1.5; 95% CI, 1.2-2.0), and rivaroxaban users (87.4 events per 1000 PYs vs 68.5 events per 1000 PYs; aHR, 1.3; 95% CI, 1.1-1.5). In all 3 comparisons, the magnitude of the benefits associated with apixaban was similar regardless of dementia diagnosis on the HR scale but differed substantially on the rate difference (RD) scale. The adjusted RD of the composite outcome per 1000 PYs for warfarin vs apixaban users was 29.8 (95% CI, 18.4-41.1) events in patients with dementia vs 16.0 (95% CI, 13.6-18.4) events in patients without dementia. The corresponding adjusted RD estimates of the composite outcome were 29.6 (95% CI, 11.6-47.6) events per 1000 PYs in patients with dementia vs 5.8 (95% CI, 1.1-10.4) events per 1000 PYs in patients without dementia for dabigatran vs apixaban users and 20.5 (95% CI, 9.9-31.1) events per 1000 PYs in patients with dementia vs 15.9 (95% CI, 11.4-20.3) events per 1000 PYs in patients without dementia for rivaroxaban vs apixaban users. The pattern was more distinct for major bleeding than for ischemic stroke.

CONCLUSIONS AND RELEVANCE: In this comparative effectiveness study, apixaban was associated with lower rates of major bleeding and ischemic stroke compared with other OACs. The increased absolute risks associated with other OACs compared with apixaban were greater among patients with dementia than those without dementia, particularly for major bleeding. These findings support the use of apixaban for anticoagulation therapy in patients living with dementia who have AF.

来源:JAMA Netw Open,查看原文。版权归原作者所有。

参考来源

  1. Lin KJ, Singer DE, Bykov K, et al. Comparative Effectiveness and Safety of Oral Anticoagulants by Dementia Status in Older Patients With Atrial Fibrillation. JAMA Netw Open. 2023. PMID: 36976562. doi:10.1001/jamanetworkopen.2023.4086

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。